한글목차

비침습적 당뇨병 치료 동향 및 전망

세계 비침습적 당뇨병 치료 시장은 2024년부터 2030년까지 연평균 5.6%의 성장률을 보일 것으로 예상됩니다. 이 시장의 주요 촉진요인은 당뇨병 유병률의 증가와 당뇨병 환자의 자가 치료 지향성 증가입니다. 세계 비침습적 당뇨병 치료 시장은 병원, 재택 의료 및 클리닉 시장에서 기회가 있고 미래가 유망한 시장입니다.

부문별 비침습적 당뇨병 치료

이 조사에는 전 세계 비침습적 당뇨병 치료의 유형별, 용도별, 지역별 예측이 포함되어 있습니다.

비침습적 당뇨병 치료 시장 인사이트

Lucintel의 예측에 따르면, 흡입 인슐린은 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.

재택의료 시장은 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

북미는 높은 당뇨병 유병률과 주요 기업들의 진출로 인해 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

자주 묻는 질문

Q1. 시장 성장 예측은?

A1. 세계 비침습적 당뇨병 치료 시장은 2024년부터 2030년까지 연평균 5.6%의 성장률을 기록할 것으로 예상됩니다.

Q2. 시장 성장에 영향을 미치는 주요 촉진요인은?

A2. 이 시장의 주요 촉진요인은 당뇨병 유병률의 증가와 당뇨병 환자의 자가 치료 지향이 증가하고 있습니다.

Q3. 시장의 주요 부문은?

A3. 비침습적 당뇨병 치료 시장의 미래는 병원, 재택의료, 진료소 시장에서의 기회로 인해 유망합니다.

Q4. 시장의 주요 기업은?

A4. 비침습적 당뇨병 치료의 주요 기업은 다음과 같습니다.

• Bio Tex
• Calisto Medical
• Dexcom
• Bayer
• ACON Laboratories

Q5. 향후 가장 큰 시장 부문은?

A5. Lucintel은 예측 기간 동안 흡입 인슐린이 가장 높은 성장률을 보일 것으로 예상하고 있습니다.

Q6. 시장에서 향후 5년간 가장 큰 시장이 될 것으로 예상되는 지역은?

A6. 북미는 당뇨병 인구가 많고 주요 기업이 존재하기 때문에 예측 기간 동안 가장 높은 성장이 예상됩니다.

Q7. 보고서 사용자 정의가 가능합니까?

A7. 예, Lucintel은 추가 비용없이 10%의 사용자 정의를 제공합니다.

목차

제1장 주요 요약

제2장 세계의 비침습적 당뇨병 치료 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2018년부터 2030년까지 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 비침습적 당뇨병 치료 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 비침습적 당뇨병 치료 시장(유형별)
  • 경구 인슐린
  • 경협 인슐린
  • 점안 인슐린
  • 흡입 인슐린
  • 경비 인슐린
  • 경피
  • 기타
• 세계의 비침습적 당뇨병 치료 시장(용도별)
  • 병원
  • 재택의료
  • 진료소
  • 기타

제4장 2018년부터 2030년까지 지역별 시장 동향과 예측 분석

• 지역별 세계의 비침습적 당뇨병 치료 시장
• 북미의 비침습적 당뇨병 치료 시장
• 유럽의 비침습적 당뇨병 치료 시장
• 아시아태평양의 비침습적 당뇨병 치료 시장
• 기타 지역비침습적 당뇨병 치료 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 업무 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 비침습적 당뇨병 치료 시장의 유형별 성장 기회
  • 세계의 비침습적 당뇨병 치료 시장의 용도별 성장 기회
  • 지역별 세계의 비침습적 당뇨병 치료 시장 성장 기회
• 세계의 비침습적 당뇨병 치료 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 비침습적 당뇨병 치료 시장 능력 확대
  • 세계의 비침습적 당뇨병 치료 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• Bio Tex
• Calisto Medical
• Dexcom
• Bayer
• ACON Laboratories

영문목차

Non-Invasive Diabetes Therapy Trends and Forecast

The future of the global non-invasive diabetes therapy market looks promising with opportunities in the hospital, home care setting, and clinic markets. The global non-invasive diabetes therapy market is expected to grow with a CAGR of 5.6% from 2024 to 2030. The major drivers for this market are rising prevalence of diabetes and growing focus on self-care among diabetes patients.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Non-Invasive Diabetes Therapy by Segment

The study includes a forecast for the global non-invasive diabetes therapy by type, application, and region.

Non-Invasive Diabetes Therapy Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Oral Insulin
• Buccal Insulin
• Ocular Insulin
• Inhaled Insulin
• Nasal Insulin
• Transdermal
• Others

Non-Invasive Diabetes Therapy Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Home Care Settings
• Clinics
• Others

Non-Invasive Diabetes Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Non-Invasive Diabetes Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies non-invasive diabetes therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the non-invasive diabetes therapy companies profiled in this report include-

• Bio Tex
• Calisto Medical
• Dexcom
• Bayer
• ACON Laboratories

Non-Invasive Diabetes Therapy Market Insights

Lucintel forecasts that inhaled insulin is expected to witness the highest growth over the forecast period.

Within this market, home care setting is expected to witness the highest growth over the forecast period.

North America is expected to witness the highest growth over the forecast period due to high diabetes prevalence among population and presence of key players in the region.

Features of the Global Non-Invasive Diabetes Therapy Market

Market Size Estimates: Non-invasive diabetes therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Non-invasive diabetes therapy market size by type, application, and region in terms of value ($B).

Regional Analysis: Non-invasive diabetes therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the non-invasive diabetes therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the non-invasive diabetes therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for non-invasive diabetes therapy market?

Answer: The global non-invasive diabetes therapy market is expected to grow with a CAGR of 5.6% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the non-invasive diabetes therapy market?

Answer: The major drivers for this market are rising prevalence of diabetes and growing focus on self-care among diabetes patients.

Q3. What are the major segments for non-invasive diabetes therapy market?

Answer: The future of the non-invasive diabetes therapy market looks promising with opportunities in the hospital, home care setting, and clinic markets.

Q4. Who are the key non-invasive diabetes therapy market companies?

Answer: Some of the key non-invasive diabetes therapy companies are as follows:

• Bio Tex
• Calisto Medical
• Dexcom
• Bayer
• ACON Laboratories

Q5. Which non-invasive diabetes therapy market segment will be the largest in future?

Answer: Lucintel forecasts that inhaled insulin is expected to witness the highest growth over the forecast period.

Q6. In non-invasive diabetes therapy market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period due to high diabetes prevalence among population and presence of key players in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the non-invasive diabetes therapy market by type (oral insulin, buccal insulin, ocular insulin, inhaled insulin, nasal insulin, transdermal, and others), application (hospitals, home care settings, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Non-Invasive Diabetes Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Non-Invasive Diabetes Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Non-Invasive Diabetes Therapy Market by Type
  • 3.3.1: Oral Insulin
  • 3.3.2: Buccal Insulin
  • 3.3.3: Ocular Insulin
  • 3.3.4: Inhaled Insulin
  • 3.3.5: Nasal Insulin
  • 3.3.6: Transdermal
  • 3.3.7: Others
• 3.4: Global Non-Invasive Diabetes Therapy Market by Application
  • 3.4.1: Hospitals
  • 3.4.2: Home Care Settings
  • 3.4.3: Clinics
  • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Non-Invasive Diabetes Therapy Market by Region
• 4.2: North American Non-Invasive Diabetes Therapy Market
  • 4.2.1: North American Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
  • 4.2.2: North American Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
• 4.3: European Non-Invasive Diabetes Therapy Market
  • 4.3.1: European Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
  • 4.3.2: European Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
• 4.4: APAC Non-Invasive Diabetes Therapy Market
  • 4.4.1: APAC Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
  • 4.4.2: APAC Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
• 4.5: ROW Non-Invasive Diabetes Therapy Market
  • 4.5.1: ROW Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
  • 4.5.2: ROW Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Type
  • 6.1.2: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Application
  • 6.1.3: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Region
• 6.2: Emerging Trends in the Global Non-Invasive Diabetes Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Non-Invasive Diabetes Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Non-Invasive Diabetes Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Bio Tex
• 7.2: Calisto Medical
• 7.3: Dexcom
• 7.4: Bayer
• 7.5: ACON Laboratories